Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.37 Analyst target: $6.00 Upside: 1533.99%
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.